ALDA Pharmaceuticals Corp.
TSX VENTURE : APH

ALDA Pharmaceuticals Corp.

May 06, 2008 09:15 ET

ALDA to Request Human Trials for T36® Skin Antiseptic

VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 6, 2008) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)("ALDA") announces that it has received the final results from BioScience Laboratories, Inc. for the T36® formulation ("T36®") tested against 10 different types of viruses. Of these, 5 types were killed within the minimum 30-second time required by the FDA, including Herpes Types I and II and Influenza B. The remaining 5 types, including Polio and Hepatitis A, the hardiest viruses, were killed within 1 to 3 minutes.

Successful completion of these tests allows ALDA to approach Health Canada with a Clinical Trial Application ("CTA") for testing of T36® as a skin antiseptic for surgical use and for personal sanitation. Once the CTA has been approved by Health Canada, human trials can begin. ALDA can also request a "pre-IND" (pre-Investigational New Drug) meeting with the FDA for the same indications. This meeting will determine if any additional tests are required by the FDA before human trials can begin in the US.

Dr. Terrance Owen, President & CEO, states, "This is an important milestone for ALDA. Now that ALDA has successfully passed all of the initial microbial tests, we can advance to the next stage and request human trials for registration of T36® as a skin antiseptic for institutional and consumer use. From our extensive toxicology studies, we know that T36® is very safe, as well as being very effective. On this basis, we are hoping for a positive outcome from these meetings."

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T36® technology. The company trades on the TSX Venture Exchange under the symbol APH.

ALDA Pharmaceuticals Corp.

Terrance G. Owen, Ph.D., MBA, President, CEO and Director

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • ALDA Pharmaceuticals Corp.
    Terrance G. Owen, Ph.D., MBA
    President, CEO and Director
    (604) 521-8300
    or
    ALDA Pharmaceuticals Corp.
    Peter Chen
    Distribution & Sales Contact
    (604) 521- 8300 Ext. 3
    (604) 521-8322 (FAX)
    Email: peter_chen@aldacorp.com
    or
    ALDA Pharmaceuticals Corp.
    Scott Young
    Investor Relations Contact
    (604) 288-7222
    Email: syoung@freeformcom.com
    Website: www.aldacorp.com